AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: A study confirmed that in an imatinib-resistant chronic myeloid leukemia (CML) cell line, dasatinib improved apoptosis through diminishing Akt/mTOR activities while abolished exosome secretion and autophagy by attenuating beclin 1 and Vps34 expression [173].